229 related articles for article (PubMed ID: 35231500)
1. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.
Sachse M; Tenorio R; Fernández de Castro I; Muñoz-Basagoiti J; Perez-Zsolt D; Raïch-Regué D; Rodon J; Losada A; Avilés P; Cuevas C; Paredes R; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N; Risco C
Antiviral Res; 2022 Apr; 200():105270. PubMed ID: 35231500
[TBL] [Abstract][Full Text] [Related]
2. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
White KM; Rosales R; Yildiz S; Kehrer T; Miorin L; Moreno E; Jangra S; Uccellini MB; Rathnasinghe R; Coughlan L; Martinez-Romero C; Batra J; Rojc A; Bouhaddou M; Fabius JM; Obernier K; Dejosez M; Guillén MJ; Losada A; Avilés P; Schotsaert M; Zwaka T; Vignuzzi M; Shokat KM; Krogan NJ; García-Sastre A
Science; 2021 Feb; 371(6532):926-931. PubMed ID: 33495306
[TBL] [Abstract][Full Text] [Related]
3. Computational Prediction of the Potential Target of SARS-CoV-2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM-PBSA Calculations.
El Hassab MA; Hemeda LR; Elsayed ZM; Al-Rashood ST; Abdel-Hamid Amin MK; Abdel-Aziz HA; Eldehna WM
Chem Biodivers; 2022 Feb; 19(2):e202100719. PubMed ID: 34813168
[TBL] [Abstract][Full Text] [Related]
4. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
Salas Rojas M; Silva Garcia R; Bini E; Pérez de la Cruz V; León Contreras JC; Hernández Pando R; Bastida Gonzalez F; Davila-Gonzalez E; Orozco Morales M; Gamboa Domínguez A; Sotelo J; Pineda B
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477376
[TBL] [Abstract][Full Text] [Related]
5. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
Martinez MA
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558296
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2: Ultrastructural Characterization of Morphogenesis in an In Vitro System.
Barreto-Vieira DF; da Silva MAN; de Almeida ALT; Rasinhas ADC; Monteiro ME; Miranda MD; Motta FC; Siqueira MM; Girard-Dias W; Archanjo BS; Bozza PT; L Souza TM; Gomes Dias SS; Soares VC; Barth OM
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215794
[TBL] [Abstract][Full Text] [Related]
7. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
Vishvakarma VK; Singh MB; Jain P; Kumari K; Singh P
Amino Acids; 2022 Feb; 54(2):205-213. PubMed ID: 34807314
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.
Aguareles J; Villares Fernández P; Forné C; Martí-Ballesteros EM; Pradillo Fernández V; Sotres-Fernandez G; de la Fuente-Burguera A; Navarro-San Francisco C; Buzón-Martín LM; García-Delangue T; Aiello FT; Carnevali-Ruiz D; Lloris R; Luepke-Estefan XE; López-Martín JA; Jimeno JM; García-Casas A; Guisado-Vasco P
Infect Dis (Lond); 2024 Jul; 56(7):575-580. PubMed ID: 38743059
[TBL] [Abstract][Full Text] [Related]
9. Morphology and morphogenesis of SARS-CoV-2 in Vero-E6 cells.
Barreto-Vieira DF; da Silva MAN; Garcia CC; Miranda MD; Matos ADR; Caetano BC; Resende PC; Motta FC; Siqueira MM; Girard-Dias W; Archanjo BS; Barth OM
Mem Inst Oswaldo Cruz; 2021; 116():e200443. PubMed ID: 33566951
[TBL] [Abstract][Full Text] [Related]
10. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology.
Ogando NS; Dalebout TJ; Zevenhoven-Dobbe JC; Limpens RWAL; van der Meer Y; Caly L; Druce J; de Vries JJC; Kikkert M; Bárcena M; Sidorov I; Snijder EJ
J Gen Virol; 2020 Sep; 101(9):925-940. PubMed ID: 32568027
[TBL] [Abstract][Full Text] [Related]
11. Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies.
Nguyen HT; Falzarano D; Gerdts V; Liu Q
J Virol; 2021 Aug; 95(18):e0068721. PubMed ID: 34191580
[TBL] [Abstract][Full Text] [Related]
12. JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis.
Son J; Huang S; Zeng Q; Bricker TL; Case JB; Zhou J; Zang R; Liu Z; Chang X; Darling TL; Xu J; Harastani HH; Chen L; Gomez Castro MF; Zhao Y; Kohio HP; Hou G; Fan B; Niu B; Guo R; Rothlauf PW; Bailey AL; Wang X; Shi PY; Martinez ED; Brody SL; Whelan SPJ; Diamond MS; Boon ACM; Li B; Ding S
mBio; 2022 Feb; 13(1):e0337721. PubMed ID: 35038906
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
14. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
Reina J
Rev Esp Quimioter; 2021 Oct; 34(5):402-407. PubMed ID: 33902254
[TBL] [Abstract][Full Text] [Related]
15. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
Müller C; Obermann W; Karl N; Wendel HG; Taroncher-Oldenburg G; Pleschka S; Hartmann RK; Grünweller A; Ziebuhr J
Antiviral Res; 2021 Feb; 186():105012. PubMed ID: 33422611
[TBL] [Abstract][Full Text] [Related]
16. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
17. Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19.
Papapanou M; Papoutsi E; Giannakas T; Katsaounou P
J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357135
[TBL] [Abstract][Full Text] [Related]
18. Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.
Bhatt AN; Kumar A; Rai Y; Kumari N; Vedagiri D; Harshan KH; Chinnadurai V; Chandna S
Life Sci; 2022 Apr; 295():120411. PubMed ID: 35181310
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
Varona JF; Landete P; Lopez-Martin JA; Estrada V; Paredes R; Guisado-Vasco P; Fernandez de Orueta L; Torralba M; Fortun J; Vates R; Barberan J; Clotet B; Ancochea J; Carnevali D; Cabello N; Porras L; Gijon P; Monereo A; Abad D; Zuñiga S; Sola I; Rodon J; Vergara-Alert J; Izquierdo-Useros N; Fudio S; Pontes MJ; de Rivas B; Giron de Velasco P; Nieto A; Gomez J; Aviles P; Lubomirov R; Belgrano A; Sopesen B; White KM; Rosales R; Yildiz S; Reuschl AK; Thorne LG; Jolly C; Towers GJ; Zuliani-Alvarez L; Bouhaddou M; Obernier K; McGovern BL; Rodriguez ML; Enjuanes L; Fernandez-Sousa JM; Krogan NJ; Jimeno JM; Garcia-Sastre A
Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35012962
[TBL] [Abstract][Full Text] [Related]
20. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
